1. Home
  2. TBPH vs CPAC Comparison

TBPH vs CPAC Comparison

Compare TBPH & CPAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • CPAC
  • Stock Information
  • Founded
  • TBPH 2013
  • CPAC 1949
  • Country
  • TBPH United States
  • CPAC Peru
  • Employees
  • TBPH N/A
  • CPAC N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • CPAC Building Materials
  • Sector
  • TBPH Health Care
  • CPAC Industrials
  • Exchange
  • TBPH Nasdaq
  • CPAC Nasdaq
  • Market Cap
  • TBPH 699.0M
  • CPAC 580.5M
  • IPO Year
  • TBPH N/A
  • CPAC 2012
  • Fundamental
  • Price
  • TBPH $14.26
  • CPAC $7.21
  • Analyst Decision
  • TBPH Strong Buy
  • CPAC Hold
  • Analyst Count
  • TBPH 4
  • CPAC 1
  • Target Price
  • TBPH $23.00
  • CPAC $6.40
  • AVG Volume (30 Days)
  • TBPH 301.7K
  • CPAC 7.0K
  • Earning Date
  • TBPH 11-11-2025
  • CPAC 10-27-2025
  • Dividend Yield
  • TBPH N/A
  • CPAC 7.00%
  • EPS Growth
  • TBPH N/A
  • CPAC 26.68
  • EPS
  • TBPH 0.26
  • CPAC 0.14
  • Revenue
  • TBPH $77,205,000.00
  • CPAC $572,828,408.00
  • Revenue This Year
  • TBPH $79.82
  • CPAC N/A
  • Revenue Next Year
  • TBPH N/A
  • CPAC N/A
  • P/E Ratio
  • TBPH $54.87
  • CPAC $10.10
  • Revenue Growth
  • TBPH 24.49
  • CPAC 3.37
  • 52 Week Low
  • TBPH $7.90
  • CPAC $5.10
  • 52 Week High
  • TBPH $15.15
  • CPAC $7.32
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 54.96
  • CPAC 60.04
  • Support Level
  • TBPH $13.50
  • CPAC $7.16
  • Resistance Level
  • TBPH $14.59
  • CPAC $7.28
  • Average True Range (ATR)
  • TBPH 0.50
  • CPAC 0.16
  • MACD
  • TBPH -0.09
  • CPAC -0.01
  • Stochastic Oscillator
  • TBPH 46.31
  • CPAC 76.60

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About CPAC Cementos Pacasmayo S.A.A. (Each representing five)

Cementos Pacasmayo SAA is a Peruvian cement company that produces, distributes, and sells cement and cement-related materials, such as concrete blocks and ready-mix concrete. The company's products are used in construction. It also produces and sells quicklime for use in mining operations. The company sells its products mainly in the northern part of Peru. It owns three cement production and transportation facilities. Its flagship Pacasmayo facility is located in the northwest region of Peru, while its new cement plant in Piura and smaller Rioja facility are located in the northeast region of Peru.

Share on Social Networks: